STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers

  • Life Sci Alliance. 2020 May 28;3(7):e202000725. doi: 10.26508/lsa.202000725.
Petra van der Lelij  1 Joseph A Newman  2 Simone Lieb  3 Julian Jude  1 Vittorio Katis  2 Thomas Hoffmann  1 Matthias Hinterndorfer  1 Gerd Bader  3 Norbert Kraut  3 Mark A Pearson  3 Jan-Michael Peters  1  4 Johannes Zuber  5  4 Opher Gileadi  6 Mark Petronczki  7
Affiliations
  • 1. Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
  • 2. Structural Genomics Consortium, University of Oxford, Oxford, UK.
  • 3. Boehringer Ingelheim Regional Center Vienna (RCV) GmbH & Co KG, Vienna, Austria.
  • 4. Medical University of Vienna, VBC, Vienna, Austria.
  • 5. Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria [email protected].
  • 6. Structural Genomics Consortium, University of Oxford, Oxford, UK [email protected].
  • 7. Boehringer Ingelheim Regional Center Vienna (RCV) GmbH & Co KG, Vienna, Austria [email protected].
Abstract

The cohesin subunit STAG2 has emerged as a recurrently inactivated tumor suppressor in human cancers. Using candidate approaches, recent studies have revealed a synthetic lethal interaction between STAG2 and its paralog STAG1 To systematically probe genetic vulnerabilities in the absence of STAG2, we have performed genome-wide CRISPR screens in isogenic cell lines and identified STAG1 as the most prominent and selective dependency of STAG2-deficient cells. Using an inducible degron system, we show that chemical genetic degradation of STAG1 protein results in the loss of sister chromatid cohesion and rapid cell death in STAG2-deficient cells, while sparing STAG2-wild-type cells. Biochemical assays and X-ray crystallography identify STAG1 regions that interact with the RAD21 subunit of the cohesin complex. STAG1 mutations that abrogate this interaction selectively compromise the viability of STAG2-deficient cells. Our work highlights the degradation of STAG1 and inhibition of its interaction with RAD21 as promising therapeutic strategies. These findings lay the groundwork for the development of STAG1-directed small molecules to exploit synthetic lethality in STAG2-mutated tumors.

Products